- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nyxoah (NYXH)
Nyxoah stock price live, this page displays EBR NYXH stock exchange data. View the NYXH premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nyxoah real time stock price chart below.
What Is the Nyxoah Stock Price Today?
The Nyxoah stock price today is 3.38.
What Is the Stock Symbol for Nyxoah?
The stock ticker symbol for Nyxoah is NYXH.
Is NYXH the Same as $NYXH?
$NYXH is a common way to refer to the Nyxoah ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Nyxoah Trade On?
Nyxoah is listed and trades on the Brussels stock exchange.
Is Nyxoah a Good Stock to Buy?
Determining whether Nyxoah—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Nyxoah share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NYXH quote. (ISIN: BE0974358906)
What Is the Nyxoah Stock Price Today?
The Nyxoah stock price today is 3.38.
What Is the Stock Symbol for Nyxoah?
The stock ticker symbol for Nyxoah is NYXH.
Is NYXH the Same as $NYXH?
$NYXH is a common way to refer to the Nyxoah ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Nyxoah Trade On?
Nyxoah is listed and trades on the Brussels stock exchange.
Is Nyxoah a Good Stock to Buy?
Determining whether Nyxoah—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Nyxoah share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NYXH quote. (ISIN: BE0974358906)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.23
3.41
52 wk Range
2.76
8.64
NYXH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.233.41
52 wk Range
2.768.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NYXH Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 6K Nyxoah For: 19 March
- Investing.com
- Nyxoah NAQ receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SWOT Analysis
Growth Potential | Learn about Nyxoah's vast market opportunity in OSA treatment, with a €10 billion annual potential in Europe and over $34 billion in the U.S. across key segments. |
Financial Outlook | Analysts maintain a bullish consensus with an average price target of $16.33, significantly above current levels, despite mixed recent financial performance. |
Market Expansion Hurdles | Delve into Nyxoah's European market challenges, including recent setbacks in Germany, and its strategic preparations for entering the lucrative U.S. market. |
Innovative OSA Treatment | Explore Nyxoah's Genio system, a groundbreaking approach to hypoglossal nerve stimulation therapy for obstructive sleep apnea, offering unique bilateral stimulation. |
Nyxoah Earnings Call Summary for Q3/2025
- Nyxoah reported Q3 2025 revenue of €2M (up 56% YoY), missing the €2.27M forecast, which triggered a 6.51% stock decline in aftermarket trading
- Operating loss widened to €24.4M from €15M last year, while gross margins declined from 62% to 60.5%, raising investor concerns despite FDA approval of Genio device
- Company secured $77M in new capital, extending cash runway to Q1 2027, and completed initial U.S. implants following successful FDA approval
- Management provided Q4 2025 global revenue guidance of €3.4-3.6M, with plans to expand U.S. commercial operations and develop an AI-integrated next-generation device
- CEO Olivier Taelman emphasized the strategic importance of managing sleep apnea as a chronic condition, with Genio implants currently priced at approximately $25,000
Last Updated: 11/13/2025, 05:41 PM
Read Full TranscriptCompare NYXH to Peers and Sector
Metrics to compare | NYXH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYXHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −7.6x | −0.5x | |
PEG Ratio | 0.05 | −0.09 | 0.00 | |
Price / Book | 2.5x | 2.3x | 2.6x | |
Price / LTM Sales | 12.4x | 2.6x | 3.2x | |
Upside (Analyst Target) | 202.0% | 61.2% | 47.6% | |
Fair Value Upside | Unlock | 5.9% | 6.1% | Unlock |
Earnings
Latest Release
Mar 19, 2026
EPS / Forecast
-0.68 / -0.62
Revenue / Forecast
6.52M / 4.05M
People Also Watch
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.